Literature DB >> 20826634

Potential influence of more-sensitive HIV-1 load detection by the new Roche Cobas AmpliPrep/Cobas TaqMan version 2.0 assay on clinical management of HIV-positive pregnant women.

M G J de Boer1, E Wessels, E C J Claas, F P Kroon.   

Abstract

With the introduction of the new Roche Cobas AmpliPrep/Cobas TaqMan version 2.0 assay, HIV-1 viral loads will be detected more frequently during the peripartum period in pregnant HIV-positive women. The implications for the clinical management of these patients are discussed in this paper.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20826634      PMCID： PMC3020870          DOI： 10.1128/JCM.00598-10

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  7 in total

1.  Performance of the new Roche Cobas AmpliPrep-Cobas TaqMan version 2.0 human immunodeficiency virus type 1 assay.

Authors:  Lesley Scott; Sergio Carmona; Wendy Stevens
Journal:  J Clin Microbiol       Date:  2009-08-05       Impact factor: 5.948

2.  Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. Women and Infants Transmission Study Group.

Authors:  P M Garcia; L A Kalish; J Pitt; H Minkoff; T C Quinn; S K Burchett; J Kornegay; B Jackson; J Moye; C Hanson; C Zorrilla; J F Lew
Journal:  N Engl J Med       Date:  1999-08-05       Impact factor: 91.245

3.  Perinatal transmission of human immunodeficiency virus type 1 by pregnant women with RNA virus loads <1000 copies/ml.

Authors:  J P Ioannidis; E J Abrams; A Ammann; M Bulterys; J J Goedert; L Gray; B T Korber; M J Mayaux; L M Mofenson; M L Newell; D E Shapiro; J P Teglas; C M Wilfert
Journal:  J Infect Dis       Date:  2001-01-12       Impact factor: 5.226

4.  Performance evaluation of the new Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test version 2.0 for quantification of human immunodeficiency virus type 1 RNA.

Authors:  Suzan Pas; John W A Rossen; Daniel Schoener; Diana Thamke; Annika Pettersson; Reiner Babiel; Martin Schutten
Journal:  J Clin Microbiol       Date:  2010-02-17       Impact factor: 5.948

5.  Transient viremia, plasma viral load, and reservoir replenishment in HIV-infected patients on antiretroviral therapy.

Authors:  Laura E Jones; Alan S Perelson
Journal:  J Acquir Immune Defic Syndr       Date:  2007-08-15       Impact factor: 3.731

6.  Evaluation of the new VERSANT HIV-1 RNA 1.0 Assay (kPCR) for quantitative detection of human immunodeficiency virus type 1 RNA.

Authors:  Katharina T Troppan; Evelyn Stelzl; Deborah Violan; Michaela Winkler; Harald H Kessler
Journal:  J Clin Virol       Date:  2009-07-02       Impact factor: 3.168

7.  Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals.

Authors:  Ninon Taylor; Ilse Schmid; Alexander Egle; Richard Greil; Wolfgang Patsch; Hannes Oberkofler
Journal:  Antivir Ther       Date:  2009
  7 in total
  2 in total

1.  Cross-platform analysis of HIV-1 RNA data generated by a multicenter assay validation study with wide geographic representation.

Authors:  Cheryl Jennings; Brian Harty; Suzanne Granger; Carrie Wager; John A Crump; Susan A Fiscus; James W Bremer
Journal:  J Clin Microbiol       Date:  2012-06-12       Impact factor: 5.948

2.  Increased risk of virologic rebound in patients on antiviral therapy with a detectable HIV load <48 copies/mL.

Authors:  Timothy J Henrich; Brian R Wood; Daniel R Kuritzkes
Journal:  PLoS One       Date:  2012-11-15       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.